NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $275 | -99.9% | 110,531 | -21.9% | 0.00% | -50.0% |
Q3 2022 | $505,000 | -15.4% | 141,551 | -10.8% | 0.00% | -20.0% |
Q2 2022 | $597,000 | -17.3% | 158,666 | +2.4% | 0.01% | 0.0% |
Q1 2022 | $722,000 | -57.3% | 154,921 | -0.1% | 0.01% | -58.3% |
Q4 2021 | $1,690,000 | +24.1% | 155,026 | +86.1% | 0.01% | +50.0% |
Q3 2021 | $1,362,000 | +4.7% | 83,311 | -16.3% | 0.01% | 0.0% |
Q2 2021 | $1,301,000 | -34.8% | 99,545 | -1.8% | 0.01% | -33.3% |
Q1 2021 | $1,995,000 | +14.4% | 101,353 | -3.7% | 0.01% | +9.1% |
Q4 2020 | $1,744,000 | -7.5% | 105,286 | -2.0% | 0.01% | -21.4% |
Q3 2020 | $1,885,000 | -27.6% | 107,442 | -1.0% | 0.01% | -30.0% |
Q2 2020 | $2,605,000 | +31.8% | 108,480 | +7.6% | 0.02% | +11.1% |
Q1 2020 | $1,977,000 | -4.0% | 100,851 | -0.6% | 0.02% | +12.5% |
Q4 2019 | $2,059,000 | +265.7% | 101,469 | +197.1% | 0.02% | +300.0% |
Q3 2019 | $563,000 | -45.8% | 34,156 | +5.2% | 0.00% | -50.0% |
Q2 2019 | $1,038,000 | -7.7% | 32,468 | +3.4% | 0.01% | -11.1% |
Q1 2019 | $1,125,000 | -16.5% | 31,406 | -0.9% | 0.01% | -18.2% |
Q4 2018 | $1,347,000 | -22.3% | 31,687 | -27.8% | 0.01% | -21.4% |
Q3 2018 | $1,734,000 | -17.0% | 43,898 | +1.6% | 0.01% | -6.7% |
Q2 2018 | $2,089,000 | -45.4% | 43,198 | +1.8% | 0.02% | -44.4% |
Q1 2018 | $3,827,000 | -69.1% | 42,448 | -73.7% | 0.03% | -67.1% |
Q4 2017 | $12,372,000 | +219.4% | 161,656 | -1.9% | 0.08% | +192.9% |
Q3 2017 | $3,874,000 | +3.6% | 164,797 | +1.2% | 0.03% | 0.0% |
Q2 2017 | $3,738,000 | +16.0% | 162,866 | -4.3% | 0.03% | +16.7% |
Q1 2017 | $3,223,000 | +53.2% | 170,264 | +4.6% | 0.02% | +41.2% |
Q4 2016 | $2,104,000 | -10.4% | 162,730 | +17.8% | 0.02% | -15.0% |
Q3 2016 | $2,349,000 | -1.0% | 138,177 | +1.2% | 0.02% | 0.0% |
Q2 2016 | $2,373,000 | +13.1% | 136,538 | -1.5% | 0.02% | +5.3% |
Q1 2016 | $2,098,000 | +5.3% | 138,581 | +2.4% | 0.02% | -5.0% |
Q4 2015 | $1,992,000 | +35.1% | 135,326 | +0.6% | 0.02% | +42.9% |
Q3 2015 | $1,474,000 | -55.6% | 134,498 | -49.3% | 0.01% | 0.0% |
Q2 2015 | $3,322,000 | +2272.9% | 265,530 | +2201.2% | 0.01% | +1300.0% |
Q1 2014 | $140,000 | +15.7% | 11,539 | +8.4% | 0.00% | 0.0% |
Q4 2013 | $121,000 | +8.0% | 10,649 | -0.3% | 0.00% | 0.0% |
Q3 2013 | $112,000 | -8.9% | 10,682 | 0.0% | 0.00% | 0.0% |
Q2 2013 | $123,000 | – | 10,682 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |